Location History:
- Tsukuba, JP (2016 - 2018)
- Tokyo, JP (2023 - 2024)
Company Filing History:
4 out of 529 
2 out of 2,405 
Years Active: 2016-2024
Title: Yu Kato - Innovator in Cancer Treatment
Introduction
Yu Kato is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development. With a total of 4 patents to his name, Kato's work focuses on combination therapies that target cancer effectively.
Latest Patents
Kato's latest patents include a groundbreaking combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer. The present disclosure describes combination therapies comprising an antagonist of the Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor. The use of these combination therapies aims to enhance the treatment of cancer. The multi-RTK inhibitor may be represented by a specific formula, where R can be an alkyl or cycloalkyl group, and R can also be a hydrogen atom or a halogen atom. Additionally, a tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt represented by the formula and an anti-PD-1 antibody.
Career Highlights
Throughout his career, Yu Kato has worked with notable companies such as Eisai R&D Management Co., Ltd. and Merck Sharp & Dohme Corp. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.
Collaborations
Kato has collaborated with esteemed colleagues, including Andrew Evan Denker and Kimiyo Tabata. These partnerships have played a crucial role in advancing his research and enhancing the effectiveness of his inventions.
Conclusion
Yu Kato is a distinguished inventor whose work in cancer treatment has the potential to make a significant impact on patient care. His innovative approaches and collaborations continue to drive advancements in the field.